GlaxoSmithKline Signs Contract for its Pandemic Flu Vaccine with UK Government

GlaxoSmithKlineGlaxoSmithKline (GSK) today announced that it has entered into an agreement with the UK Government to provide its pandemic influenza vaccine in the event of a flu pandemic. It is one of the largest contracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine.

As part of an Advance Supply Agreement, GSK has committed to make the necessary preparations to supply its pandemic influenza vaccine as soon as possible after a pandemic outbreak has been declared.ntracts signed by GSK to date for its proprietary adjuvanted pandemic flu vaccine. GSK plans to supply a 'tailored' pandemic vaccine as and when the pandemic strain is identified and made available by the World Health Organisation (WHO).

Andrew Witty, President GSK Pharmaceuticals Europe, said: "This agreement underlines GSK's commitment to supporting the UK Government in its plans against a possible influenza pandemic. Vaccines are considered to be the single most important intervention for preventing influenza infection and reducing spread of the disease. They are a critical component of any response plan aimed at reducing the potentially devastating effects of an influenza pandemic. GSK believes that securing a pandemic vaccine supply is an important step towards full pandemic preparedness and ultimately the protection of the British public."

The WHO has stated that an influenza pandemic poses a serious global public health threat with substantial estimated morbidity and mortality. GSK is committed to supporting governments and health authorities around the world in planning to respond to a global influenza pandemic, both prior to an outbreak and in the event one is officially declared. This latest agreement with the UK Government follows recent supply agreements signed with the Swiss, Danish and Icelandic governments. GSK has applied for registration of its pandemic vaccine in January, 2007 to the EMEA.

Professor John Oxford, Professor of Virology, Queen Mary's School of Medicine, St Bartholomew#s and the Royal London Hospitals, and Scientific Director of Retroscreen Virology Ltd said: "This announcement by the UK Government is very good news. The World Health Organisation and experts across the globe agree that an influenza pandemic is likely to occur, but cannot predict when. Despite this uncertainty, there is still the opportunity to be thoroughly prepared. This agreement is part of the preparation needed to protect the UKpopulation when an influenza pandemic eventually strikes."

The pandemic vaccine utilises GSK's proprietary adjuvant system technology which has been shown to reduce the amount of antigen required to elicit a seroprotective response – the so-called 'antigen-sparing' effect. This allows a greater number of vaccine doses to be produced when antigen availability is likely to be limited, thereby offering the potential for vaccination to more people in the event of a flu pandemic. In recent pre-clinical trials the adjuvanted vaccine has shown the potential to recognize different H5N1 viruses and to induce cross-protection.

Since 2000, GSK has made substantial progress in its pandemic influenza vaccine development programme and continues to investigate ways to further improve vaccination strategies to respond to a pandemic. To this end, more than $2 billion has already been invested by GSK in combating avian flu; increasing GSK's production capacity for influenza vaccines and GSK's anti-viral flu treatment Relenza® (zanamivir), and in ensuring the continuity of critical business operations and processes, to safeguard the continued supply of critical medicines.

About GlaxoSmithKline
GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information, visit GlaxoSmithKline at www.gsk.com

Most Popular Now

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

FDA approves first treatment for Lambert-Eaton mya…

The U.S. Food and Drug Administration today approved Firdapse (amifampridine) tablets for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. LEMS is a r...

Pfizer reaches a global agreement with AbbVie

Pfizer Inc. (NYSE:PFE) has signed licensing agreements with AbbVie, resolving all global intellectual property matters for Pfizer's proposed adalimumab biosimilar. Under ...

FDA grants breakthrough device designation to arti…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Device Designation to the Artificial Intelligence Software for Chronic Thrombo...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

GSK reaches agreement to acquire TESARO, an oncolo…

GlaxoSmithKline plc (LSE/NYSE: GSK) and TESARO Inc (NASDAQ: TSRO) announced that the Companies have entered into a definitive agreement pursuant to which GSK will acquire...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Alcon to highlight its vision, strategy and benefi…

Alcon, the eye care division of Novartis, will today hold its first Capital Markets Day for investors and analysts in relation to the previously-announced intention of No...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...